Repligen Corporation (RGEN) – What Are Brokerages Saying About This Stock?

Shares of Repligen Corporation (NASDAQ:RGEN) have earned a consensus rating of “Moderate Buy” from the eighteen analysts that are presently covering the company, MarketBeat.com reports. Four equities research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and two have assigned a strong buy rating to the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $178.57.

A number of equities analysts recently issued reports on RGEN shares. Zacks Research downgraded Repligen from a “strong-buy” rating to a “hold” rating in a report on Monday, September 28th. Evercore restated an “outperform” rating and set a $160.00 price objective on shares of Repligen in a research report on Monday, July 6th. Weiss Ratings upgraded shares of Repligen from a “hold (c-)” rating to a “hold (c)” rating in a report on Thursday, October 8th. Citigroup raised shares of Repligen to a “buy” rating in a research report on Tuesday, July 7th. Finally, UBS Group reaffirmed a “buy” rating on shares of Repligen in a research report on Tuesday, September 29th.

Trending Headlines about Repligen

Here are the key news stories impacting Repligen this week:

• Positive Sentiment: Repligen reported third-quarter revenue of approximately $209.3 million, up 10.9% year over year and above the $206.7 million analyst consensus. Adjusted earnings of $0.53 per share also exceeded the $0.46 estimate. Repligen Reports Third Quarter 2026 Financial Results
• Positive Sentiment: Management raised 2026 revenue guidance to approximately $844 million-$852 million, representing reported growth of roughly 14.5%-15.5%. The completed BioLife acquisition is expected to strengthen Repligen’s position in the growing cell-therapy market. Repligen Exceeds Q3 Expectations
• Neutral Sentiment: The quarter included a $41.2 million impairment charge, turning reported quarterly profit into a loss. Because the charge is non-cash, investors appear to be placing greater emphasis on adjusted earnings and operating results, but it remains a headwind for GAAP results. Repligen Takes $41.2 Million Impairment Charge
• Negative Sentiment: Filtration revenue declined year over year, and management said some anticipated system deliveries have shifted into 2027. That delay raises concerns about near-term growth momentum despite strength in Proteins, Chromatography and Analytics. Repligen Slips as Investors Weigh Filtration Weakness

Hedge Funds Weigh In On Repligen

Large investors have recently bought and sold shares of the stock. Americana Partners LLC purchased a new position in Repligen during the 3rd quarter worth $388,000. North Dakota State Investment Board increased its stake in Repligen by 4.1% in the third quarter. North Dakota State Investment Board now owns 1,630 shares of the biotechnology company’s stock valued at $313,000 after purchasing an additional 64 shares during the period. Evergreen Capital Management LLC purchased a new stake in shares of Repligen in the third quarter valued at about $217,000. Gibbs Wealth Management raised its holdings in shares of Repligen by 7.7% in the third quarter. Gibbs Wealth Management now owns 12,866 shares of the biotechnology company’s stock valued at $2,473,000 after buying an additional 917 shares during the last quarter. Finally, Yousif Capital Management LLC raised its holdings in shares of Repligen by 1.3% in the third quarter. Yousif Capital Management LLC now owns 12,604 shares of the biotechnology company’s stock valued at $2,423,000 after buying an additional 160 shares during the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Repligen Stock Performance

Shares of RGEN stock opened at $184.69 on Friday. The company has a market cap of $10.42 billion, a P/E ratio of 253.00, a PEG ratio of 3.23 and a beta of 1.08. The firm has a fifty day moving average price of $177.88 and a 200 day moving average price of $145.08. The company has a current ratio of 9.05, a quick ratio of 7.64 and a debt-to-equity ratio of 0.26. Repligen has a 12 month low of $100.99 and a 12 month high of $198.87.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings results on Tuesday, October 27th. The biotechnology company reported $0.53 earnings per share for the quarter, beating analysts’ consensus estimates of $0.46 by $0.07. Repligen had a return on equity of 5.30% and a net margin of 5.29%. The company had revenue of $209.31 million for the quarter, compared to analysts’ expectations of $206.70 million. During the same period last year, the firm earned $0.46 earnings per share. Repligen’s quarterly revenue was up 10.9% on a year-over-year basis. Sell-side analysts predict that Repligen will post 2.06 earnings per share for the current fiscal year.

About Repligen

Repligen Corporation (NASDAQ:RGEN) develops and manufactures bioprocessing technologies used in the production of biological medicines. Its products support key stages of biopharmaceutical manufacturing, including upstream processing, downstream purification, filtration, process monitoring and fluid management.

The company’s offerings include chromatography products, filtration systems, single-use technologies, process analytics equipment and critical biological materials such as recombinant proteins.